<DOC>
	<DOCNO>NCT00003037</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase I/II trial study effectiveness combination chemotherapy docetaxel , gemcitabine , cisplatin induction therapy treat patient stage III non-small cell lung cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Induction Therapy Treating Patients With Stage III Non-small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose ( MTD ) schedule docetaxel , gemcitabine , cisplatin induction chemotherapy patient Stage III non-small cell lung cancer ( NSCLC ) schedule undergo subsequent surgical resection irradiation . II . Determine major objective response rate combination therapy patient . OUTLINE : This dose escalation study . Docetaxel administer 1 hour IV infusion week 1 , 5 , 9 . Gemcitabine administer 30 minute IV infusion week 1 , 2 , 3 , 5 , 6 , 7 , 9 , 10 , 11 . Cisplatin administer 20 minute IV infusion week 3 , 7 , 11 . In addition , G-CSF administer subcutaneously day 2 6 28 day cycle follow dose docetaxel . Three patient enter dose level must complete one cycle therapy . If patient experience dose limit toxicity ( DLT ) , 3 patient treat next high dose level . If 1 patient experience DLT , 3 patient treat dose level . If 2 6 patient experience DLT , dose declare maximum tolerate dose ( MTD ) . Once MTD determine , Phase II portion study begin additional patient treat dose level MTD . Patients show complete partial response , change , chemotherapy , undergo surgical resection radiotherapy remove reduce tumor . Patients assessed disease progression unacceptable toxicity every 4 week till end treatment . PROJECTED ACCRUAL : An estimated 40 patient accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm Stage III ( T12 N23 M0 , T3 N2 M0 , T4 N03 M0 ) nonsmall cell lung cancer Must candidate either resection curative intent definitive thoracic irradiation follow induction chemotherapy No malignant pericardial pleural effusion superior vena cava syndrome Must measurable evaluable indicator lesion PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 70100 % Hematopoietic : WBC least 4,000/mm3 Platelet count least 160,000/mm3 Hepatic : Bilirubin great 1.0 mg/dL SGOT and/or SGPT great 1.5 time upper limit normal Alkaline phosphatase great 5 time upper limit normal Renal : Creatinine clearance least 65 mL/min Cardiovascular : Must stable heart rhythm No unstable angina No myocardial infarction within 6 month No clinical evidence congestive heart failure Neurologic : Must normal auditory function No symptoms peripheral neuropathy Other : No prior malignancy except nonmelanoma skin cancer situ carcinoma cervix Not pregnant Adequate contraception require fertile patient PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior radiation therapy Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
</DOC>